Research advances of obinutuzumab in the treatment of membranous nephropathy
Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN. However, its response rate is merely 60% during a follow-up period of up to 24 months. Obinutuzumab is a type Ⅱ humanized anti-CD20 monoclona...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2024-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/cn/article/doi/10.3969/j.issn.1671-2390.2024.01.009 |